Neurology · Antiepileptic
The FDA's approval of Granules' Lamotrigine ANDA078982 is significant as it enhances competition in the generic antiepileptic market. This could impact market dynamics, pricing strategies, and market share for existing branded products.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 8/2/2026, 6:32:10 PM
Assessment confidence: 69% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's approval of Granules' Lamotrigine ANDA078982 is significant as it enhances competition in the generic antiepileptic market. This could impact market dynamics, pricing strategies, and market share for existing branded products. Regulatory context from FDA (FDA AP — LAMOTRIGINE (SUPPL)) supports the near-term read. Assessment grounded in 17 ranked evidence items (8 high-relevance).
Portfolio teams should assess the impact of this approval on market share and pricing strategies for Lamotrigine products. The strongest clinical anchor is Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine. In Neurology · Antiepileptic, 6 regulatory and 3 competitive items passed relevance filtering for Granules.
The most relevant competitive pressure comes from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Priority Review for NUPLAZID Supplement NDA210793. This approval status may enhance Granules' position in the generic antiepileptic market, potentially increasing competition against branded versions.
Regulatory risk is concentrated around FDA AP — LAMOTRIGINE (SUPPL) (FDA). Entity match (lamotrigine); Regulatory pathway relevance (nda). The approval status indicates compliance with FDA standards, but ongoing monitoring of market entry and competitor responses is necessary to assess further regulatory implications.
FDA AP — LAMOTRIGINE (SUPPL)
FDAhigh relevance
Entity match (lamotrigine); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — LAMOTRIGINE (SUPPL)
FDAhigh relevance
Entity match (lamotrigine); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — LAMOTRIGINE (SUPPL)
FDAhigh relevance
Entity match (lamotrigine); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (granules); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — SUBVENITE (SUPPL)
FDAhigh relevance
Entity match (lamotrigine); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (granules); Regulatory pathway relevance (nda)
FDA document
View sourceLong-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View sourceThe Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceRelationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceMenstrual Status, Anesthetic Consumption, and PONV
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceNeurophysiological Investigation of the Approach-avoidance Axis in OCD: Applications to Neuromodulation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourcePhysical and Behavioral Traits of Overweight and Obese Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for NUPLAZID Supplement NDA210793
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Pregabalin Application ANDA219593 by Unichem
Humanexa Signalsmedium relevance
Moderate corpus alignment
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval of Granules' Lamotrigine ANDA078982 is significant as it enhances competition in the generic antiepileptic market. This could impact market dynamics, pricing strategies, and market share for existing branded products.
Increased competition from Granules may lead to pricing pressures on branded Lamotrigine products, affecting revenue and market positioning.
The approval status indicates compliance with FDA standards, but ongoing monitoring of market entry and competitor responses is necessary to assess further regulatory implications.
Monitor the launch timeline and market entry of Granules' Lamotrigine product, as well as competitor responses.
Track for follow-up milestones; no immediate action required.